A, Mortality rates within 90, 180, and 365 days after LAAC are shown according to CHA2DS2-VASc (congestive heart failure; hypertension; ages ≥74 years [2 points]; diabetes; stroke, transient ischemic attack, or systemic embolism [2 points]; vascular disease; ages 65-74 years; sex [female]) score. B, Rate of ischemic stroke or TIA within 180 days after LAAC according to the CHA2DS2-VASc score is shown. C, Relative reduction (RR) in ischemic stroke risk after LAAC according to the CHA2DS2-VASc score is shown. For CHA2DS2-VASc score of 0 to 3, the expected ischemic stroke rate was 2.90 and the actual rate was 1.05 per 100 patient-years; for CHA2DS2-VASc scores of 4 to 5, the expected ischemic stroke rate was 5.84 and the actual rate was 2.31 per 100 patient-years; and for CHA2DS2-VASc scores of 6 or more, the expected ischemic stroke rate was 10.24 and the actual rate was 3.18 per 100 patient-years.
aStatistically significant difference (P < .05).
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kabra R, Girotra S, Vaughan Sarrazin M. Clinical Outcomes of Mortality, Readmissions, and Ischemic Stroke Among Medicare Patients Undergoing Left Atrial Appendage Closure via Implanted Device. JAMA Netw Open. 2019;2(10):e1914268. doi:10.1001/jamanetworkopen.2019.14268
What are the clinical outcomes among Medicare patients with atrial fibrillation undergoing left atrial appendage closure with an implanted device?
In this cohort study of 13 627 patients with atrial fibrillation who underwent left atrial appendage closure, the rate of hospitalization for stroke at 6 months (1.2%) was significantly lower than expected according to their CHA2DS2-VASc scores in the absence of anticoagulation therapy. The 1-year mortality rate (7.5%) was higher than that in previous randomized clinical trials, likely because of the inclusion of older patients with more comorbidities who were ineligible to receive warfarin.
Left atrial appendage closure via an implanted device was associated with a decreased risk of stroke in patients with atrial fibrillation.
Left atrial appendage closure (LAAC) has emerged as a nonpharmacological alternative for stroke prevention in patients with nonvalvular atrial fibrillation. Contemporary data regarding the characteristics and outcomes of patients undergoing this procedure are limited.
To determine the characteristics, postprocedural mortality rate, and rates of readmission and ischemic stroke among Medicare beneficiaries who underwent LAAC via implanted device.
Design, Setting, and Participants
This population-based cohort study used Medicare inpatient claims from January 2015 to December 2017 for 13 627 patients older than 65 years with a diagnosis of atrial fibrillation who underwent LAAC with an implanted device from January 2015 to November 2017. Data analyses were conducted from January through August 2019.
Left atrial appendage closure.
Main Outcomes and Measures
Mortality rates during the index admission and for 1 year after LAAC were assessed. The 30-day readmission rate and the primary reasons for readmission were also examined. In addition, the likelihood of hospitalization for ischemic stroke within 180 days among 9231 patients for whom 6 months of follow-up data were available was evaluated.
Among the 13 627 patients undergoing LAAC, the mean (SD) age was 78.0 (6.3) years, 9406 (69.0%) were older than 75 years, 11 980 (87.9%) were white, and 5630 (41.3%) were women. The mean (SD) CHA2DS2-VASc score was 4.3 (1.4). Twenty-eight patients (0.2%) died during the index admission. Mortality rates were 0.6% (80 patients) at 30 days, 1.9% (262 patients) at 90 days, 4.0% (547 patients) at 180 days, and 7.5% (1027 patients) at 365 days. The 30-day readmission rate among 13 599 patients discharged alive was 9.4% (1284 patients). Among 9231 patients with 6 months of follow-up data, 111 (1.2%) experienced readmission for ischemic stroke or transient ischemic attack within 180 days of discharge.
Conclusions and Relevance
In this cohort study of patients older than 65 years with atrial fibrillation who underwent LAAC with an implanted device, readmission rates for ischemic strokes over the course of 6 months were lower than expected given the patients’ CHA2DS2-VASc scores in the absence of anticoagulation therapy. Mortality at 1 year was higher than that reported in previous randomized clinical trials, likely because the patients in the present study were older, had a higher number of comorbidities, and were ineligible to receive warfarin.
Atrial fibrillation (AF) has emerged as a cardiovascular epidemic, with prevalence estimated to approach 12.1 million individuals in the United States by 2030.1 It increases the risk for stroke by 4- to 5-fold and is an independent risk factor for ischemic stroke severity, recurrence, stroke-related disability, and mortality. Anticoagulation therapy is the cornerstone for stroke prevention in patients with AF, according to their CHA2DS2-VASc (congestive heart failure; hypertension; ages ≥74 years [2 points]; diabetes; stroke, transient ischemic attack [TIA], or systemic embolism [2 points]; vascular disease; ages 65-74 years; sex [female]) risk scores.2 Left atrial appendage closure (LAAC) devices have emerged as nonpharmacological alternatives for stroke prevention in patients with AF.3 The Watchman device (Boston Scientific) was the first LAAC device that was compared with warfarin in 2 randomized clinical trials: PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation; ClinicalTrials.gov identifier: NCT00129545)4 and PREVAIL (Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation vs Long Term Warfarin Therapy; ClinicalTrials.gov identifier: NCT01182441).5 The device received US Food and Drug Administration approval in 2015 for stroke prevention in patients with nonvalvular AF who are at high risk of stroke and are deemed suitable for short-term oral anticoagulation therapy but have appropriate rationale to seek nonpharmacologic alternatives to warfarin. To date, the real-world data outside clinical trials regarding the use and outcomes of LAAC devices are limited. To address this gap in knowledge, in this study, we describe the characteristics of patients undergoing LAAC via implanted device and examine the postprocedural outcomes of mortality, hospital readmissions, and ischemic stroke using Medicare data.
The study was approved by the University of Iowa institutional review board, and the need for consent was waived because of the use of encrypted patient identifiers. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.6
The study used Centers for Medicare & Medicaid Beneficiary Summary (enrollment) and Medicare Provider and Analysis Review (inpatient claims) files from January 2015 through December 2017. Patients aged 66 years and older who underwent LAAC with the Watchman device during January 2015 through November 2017 were identified in hospital discharge records in the Medicare Provider and Analysis Review files according to International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) procedure code 02L73DK (occlusion of left atrial appendage with intraluminal device, percutaneous approach). Currently, Watchman is the only intraluminal LAAC device approved by the US Food and Drug Administration for this procedure code. We obtained patient dates of death from the Beneficiary Summary File, with mortality information available up to 1 year after the LAAC. We only included patients older than 65 years who had at least 1 year of Medicare enrollment to identify comorbidities from the inpatient claims preceding LAAC.
Patient demographic characteristics (age, sex, and race/ethnicity) were identified on the Beneficiary Summary File. Comorbid conditions included in the CHA2DS2-VASc score were identified using an established algorithm according to International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and ICD-10 diagnoses on the LAAC hospital discharge record, as well as inpatient claims during the year preceding the LAAC admission.7-9
The primary outcome was mortality during admission and within 1 year of LAAC. The secondary outcomes were readmissions within 30 days after LAAC discharge and reasons for readmission among patients discharged alive. To assess reasons for readmission, all first readmissions within 30 days of discharge were categorized according to the primary diagnosis code using the US Agency for Healthcare Research and Quality Clinical Classification System,9 which collapses individual ICD-9-CM and ICD-10 codes into approximately 200 meaningful clinical categories. In addition, we evaluated the likelihood of admission for ischemic stroke or TIA within 180 days and the rate of admission for ischemic stroke or TIA per patient-year among patients discharged alive for whom at least 6 months of follow-up data were available. Admissions for ischemic stroke were identified by primary diagnosis on inpatient claims using ICD-10 codes starting with I63, I65, and I66 for ischemic stroke and G45 for TIA.
Data analyses were conducted from January through August 2019. Summary statistics for patient characteristics were described as proportions for categorical variables (sex, race/ethnicity, and patient comorbidities), or using mean and SD for continuous variables (patient age and CHA2DS2-VASc score). Mortality was expressed as the percentage of patients who died within 30, 90, and 180 days. Readmission rates for ischemic stroke and TIA were reported as the percentage of patients admitted for stroke or TIA within 180 days (among patients discharged alive after LAAC), as well as the rate of stroke or TIA admissions per patient-year of follow-up. In the latter estimate, patients were censored because of death or end of the observation period (December 31, 2017). Confidence intervals around the rate of stroke admissions were generated assuming a Poisson distribution. Stroke admission rates were reported for a composite representing ischemic stroke or TIA, as well as separately for TIA and ischemic stroke. Finally, we assessed trends in mortality and readmission rates over time and by CHA2DS2-VASc score using the Cochran-Armitage test for trend. Statistical analyses were performed using SAS statistical software version 9.4 (SAS Institute). All statistical testing was 2-tailed, with P < .05 designating statistical significance.
Overall, 13 627 patients with AF underwent LAAC with Watchman implantation from January 2015 through November 2017. The mean (SD) age was 78.0 (6.3) years, 7997 (59.7%) were men, 5630 (41.3%) were women, 9406 (69.0%) were older than 75 years, and their mean (SD) CHA2DS2-VASc score was 4.3 (1.4), which would yield an expected annual ischemic stroke risk of 4.8%, according to previous work.10 There were 11 980 white patients (87.9%), 455 black patients (3.3%), and 523 Hispanic patients (3.8%). Table 1 compares the patients undergoing LAAC in our study with those in the randomized clinical trials.4,5 Compared with the randomized trials, the patients in the current study were older (mean [SD] age, 78.0 [6.3] years vs 71.7 [8.8] years and 74.0 [7.4] years); with a higher percentage of women; higher prevalence of congestive heart failure (41.9% vs 26.8% and 23.4%), hypertension (91.8% vs 89.6% and 88.5%), and diabetes (37.1% vs 24.4% and 33.8%); and a higher mean (SD) CHA2DS2-VASc score (4.4 [1.4] vs 3.4 [1.5] and 3.8 [1.2]).
During the hospital admission for LAAC, 28 patients (0.2%) died. Over the observation period, mortality rates were 0.6% (80 patients) at 30 days, 1.9% (262 patients) at 90 days, 4.0% (547 patients) at 180 days, and 7.5% (1027 patients) at 1 year (Table 2). The 30-day readmission rate among 13 599 patients discharged alive was 9.4% (1284 patients). Among 9231 patients with 6 months of follow-up data, 111 (1.2%) experienced readmission for ischemic stroke or TIA within 180 days of discharge, with 84 patients (0.9%) readmitted for ischemic stroke and 29 patients (0.3%) readmitted for TIA. The corresponding admission rates were 2.5 readmissions per 100 patient-years (95% CI, 2.2-2.8 readmissions per 100 patient-years) for stroke or TIA, 1.9 readmissions per 100 patient-years (95% CI, 1.7-2.2 readmissions per 100 patient-years) for ischemic stroke only, and 0.6 readmissions per 100 patient-years (95% CI, 0.5-0.8 readmissions per 100 patient-years) for TIA only.
The mortality and stroke readmission rates in the present study compared with those of previous studies4,5,11-14 are shown in Table 3. The previous studies had ischemic stroke rates of 1.6%, 1.7%, and 1.1% and mortality rates of 3.6%, 5.0%, and 9.8%, respectively. We discuss these comparisons in greater detail later in the article.
We further examined mortality and readmission rates for stroke and TIA by CHA2DS2-VASc score (Table 2 and Figure). All outcomes were more frequent among patients with higher CHA2DS2-VASc scores. In particular, among those with higher CHA2DS2-VASc scores, mortality rates were higher within 90 days (score 0-3, 1.1%; score 4-5, 1.8%, score ≥6, 3.5%; P < .001), within 180 days (score 0-3, 2.3%; score 4-5, 3.8%; score ≥6, 7.1%; P < .001), and within 365 days (score 0-3, 4.0%; score 4-5, 7.7%; score ≥6, 12.0%; P < .001). We compared the observed rates of ischemic stroke after LAAC via implanted device in our study with expected stroke rates in the absence of anticoagulation therapy according to CHA2DS2-VASc scores, using data from prior studies.10 We noted a 60% to 69% relative reduction in stroke risk after LAAC, compared with the risk in the absence of anticoagulation therapy (Figure).
The most frequent primary diagnoses for readmissions within 30 days were gastrointestinal hemorrhage (134 patients [1.0%]), hypertension with complications (111 patients [0.8%]), cardiac dysrhythmias (103 patients [0.8%]), complications from a device or surgical procedure (84 patients [0.6%]), and septicemia (68 patients [0.5%]). There were 28 readmissions (0.30%) for hemorrhagic stroke within 180 days after LAAC via implanted device.
To our knowledge, this is the largest study outside clinical trial to assess the characteristics of patients with AF undergoing LAACs and the associated outcomes of mortality, readmissions, and stroke. We noted that, compared with previous randomized clinical trials,4,5 our study had a higher percentage of women, and the patients had higher numbers of comorbidities and higher CHA2DS2-VASc scores. The risk of readmission for stroke (1.2% at 6 months) was significantly lower than that expected according to the mean (SD) CHA2DS2-VASc score of 4.3 (1.4) in the absence of anticoagulation therapy, which would yield an expected annual ischemic stroke risk of 4.8%, according to previous work.10
A recent meta-analysis11 of the PROTECT AF4 and PREVAIL5 randomized clinical trials compared 5-year outcomes for the 732 patients who underwent LAAC with the Watchman device with 382 patients in the control group treated with warfarin. In the LAAC groups of those studies,4,5 the incidence of ischemic stroke or systemic embolism was 1.6% per 100 patient-years, and the overall mortality rate was 3.6% per 100 patient-years. Left atrial appendage closure was associated with lower risk of all-cause mortality, as well as cardiovascular or unknown death, compared with warfarin. In the present study, readmission for ischemic stroke occurred in 111 of 9231 patients (1.2%) within 180 days after LAAC implantation. We observed a mortality rate of 7.5% at 1 year, and 28 patients (0.2%) died during the index admission for LAAC. There can be several explanations for the slightly higher rates of stroke and mortality in our study compared with the randomized clinical trials.4,5 Our study included an older patient population (aged >65 years) with higher numbers of comorbidities and higher CHA2DS2-VASc scores. Patients in the randomized clinical trials had to be eligible to receive warfarin to participate, which would likely preselect a healthier population. In contrast, eligibility for long-term anticoagulation therapy is not a requirement for the device implantation in clinical practice.
In the ASAP (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology) nonrandomized study,12,13 150 patients with AF who were not eligible for oral anticoagulation therapy underwent LAAC. Patients received aspirin and clopidogrel for 6 months after implantation and aspirin thereafter. The annualized ischemic stroke and systemic embolization rate was 1.7%, and the mortality rate at 1 year was 5.0%. Another long-term nonrandomized prospective real-world study from Europe, EWOLUTION (Registry on Watchman Outcomes in Real Life Utilization),14 reported 1-year outcome data for 1025 patients undergoing LAAC. The annual rate of ischemic stroke was 1.1% (15 of 1325 patient-years), and the 1-year mortality rate was 9.8%. Many of these patients were not eligible for anticoagulation therapy and underwent LAAC as a last resort option for stroke prevention. In both studies,12-14 the rate of stroke was lower than that in the present study. However, as observed in the present study, the 1-year mortality rate was significantly higher than those in the randomized studies,4,5 possibly because of the inclusion of patients with higher numbers of comorbidities.
This study is retrospective and based on Medicare claims data, which have inherent limitations. We only included patients older than 65 years; therefore, our results cannot be extrapolated to younger patient populations. Specific details regarding LAAC via device implantation, immediate complications, preimplantation and postimplantation antithrombotic therapy, or postimplantation left atrial appendage imaging results were not available. The exact cause of death and whether it was related to the Watchman implantation procedure were unclear.
In this retrospective real-world study of Medicare patients older than 65 years with AF, LAAC via implanted device was associated with a decreased risk of admission for stroke compared with the expected risk without anticoagulation therapy. The risks of 1-year mortality and stroke at 6 months were higher than those in previous randomized clinical trials, likely because the population in the current study was older and had more comorbidities and higher CHA2DS2-VASc scores. Although LAAC provides an attractive nonpharmacological option for stroke prevention in patients with AF who are not candidates for long-term anticoagulation therapy, further prospective long-term real-world studies are needed to monitor its safety and efficacy.
Accepted for Publication: September 9, 2019.
Published: October 30, 2019. doi:10.1001/jamanetworkopen.2019.14268
Correction: This article was corrected on November 22, 2019, to correct 3 numbers that appear in the Results, Discussion, and Table 3.
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Kabra R et al. JAMA Network Open.
Corresponding Author: Mary Vaughan Sarrazin, PhD, Department of Internal Medicine, University of Iowa College of Medicine, 200 Hawkins Dr, Iowa City, IA 52246 (firstname.lastname@example.org).
Author Contributions: Dr Sarrazin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Kabra, Vaughan Sarrazin.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Kabra.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Kabra, Vaughan Sarrazin.
Obtained funding: Vaughan Sarrazin.
Administrative, technical, or material support: Kabra.
Supervision: Vaughan Sarrazin.
Conflict of Interest Disclosures: Dr Girotra reported receiving grants from the National Heart, Lung, and Blood Institute and the Department of Veterans Affairs Health Services Research and Development Service during the conduct of the study. No other disclosures were reported.
Funding/Support: Dr Vaughan Sarrazin was supported by award R01-AG055663 from the National Institutes of Health and by the Health Services Research and Development Service of the US Department of Veterans Affairs.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs.
Create a personal account or sign in to: